Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Certificates

Data access

Data access restrictions

Database access

Database access restrictions

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 8 result(s)
Country
Since 2004, the Leibniz Institute for Prevention Research and Epidemiology – BIPS has been working on the establishment and maintenance of the project-based German Pharmacoepidemiological Research Database (short GePaRD). GePaRD is based on claims data from statutory health insurance (SHI) providers and currently includes information on about 20 million persons who have been insured with one of the participating providers since 2004. Per data year, there is information on approximately 17% of the general population from all geographical regions of Germany.
Country
The Biobanque québécoise de la COVID-19 (BQC19) is a pan-provincial initiative that collects, stores and shares data and blood samples from COVID-19 patients, both severe and non-severe cases and control cases, in an effort to respond effectively to the public health challenges posed by the pandemic. BQC19 believes that better understanding the disease will help society in returning to social activities and in preparing for future pandemics. It sees access to high-quality samples and data as essential in fulfilling research and works to bring about national and international research collaborations.
Country
InTOR is the institutional digital repository of the Institute of Virology, Vaccines and Sera “Torlak”. It provides open access to publications and other research outputs resulting from the projects implemented by the Institute of Virology, Vaccines and Sera “Torlak”. The software platform of the repository is adapted to the modern standards applied in the dissemination of scientific publications and is compatible with international infrastructure in this field.
Country
From April 2020 to March 2023, the Covid-19 Immunity Task Force (CITF) supported 120 studies to generate knowledge about immunity to SARS-CoV-2. The subjects addressed by these studies include the extent of SARS-CoV-2 infection in Canada, the nature of immunity, vaccine effectiveness and safety, and the need for booster shots among different communities and priority populations in Canada. The CITF Databank was developed to further enhance the impact of CITF funded studies by allowing additional research using the data collected from CITF-supported studies. The CITF Databank centralizes and harmonizes individual-level data from CITF-funded studies that have met all ethical requirements to deposit data in the CITF Databank and have completed a data sharing agreement. The CITF Databank is an internationally unique resource for sharing epidemiological and laboratory data from studies about SARS-CoV-2 immunity in different populations. The types of research that are possible with data from the CITF Databank include observational epidemiological studies, mathematical modelling research, and comparative evaluation of surveillance and laboratory methods.
<<<!!!<<< This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information. Please go to www.ahrq.gov for current information. >>>!!!>>> HIV and AIDS Costs and Use is the first major research effort to collect information on a nationally representative sample of people in care for HIV infection. Also called the HIV Cost and Services Utilization Study (HCSUS), the core study is meant to help policymakers in the U.S. make informed decisions on the subject. The study describes the type of therapies available and costs of health care services for people with HIV/AIDS, as well as quality of care, social support, and non-medical services HIV/AIDS patients receive. Supplemental studies examine HIV care delivery in rural areas, prevalence of mental and substance abuse disorders, and other health issues of HIV/AIDS patients.